You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

The Use of Targeted Therapies in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Updated Guideline 2017

Version: 2 ID: 3-8-4 May 2017
Type of Content: Guidelines & Advice, Clinical
Document Status: In-Review
S. Hotte, J. Brown, C. Canil, U. Emmenegger, C. Walker-Dilks, E. Winquist, Genitourninary Disease Site Group

Guideline Objective

The primary objective of this report is to determine the optimal targeted therapies for locally advanced or metastatic renal cell cancer (mRCC). The secondary objective is to determine whether a combination of targeted agents is better than any single targeted agent.

Patient Population

Adult patients with inoperable locally advanced or mRCC.

Intended Guideline Users

Oncologists who treat patients with RCC.

Research Questions

What are the optimal targeted therapies for locally advanced or mRCC?

pdf download Summary (PDF) (78.97 KB)
pdf download Full Report (PDF) (516.17 KB)